PharmacoEconomics & Outcomes News 652 - 28 Apr 2012 ASCO’s "top five" costly overused interventions ASCO * has identified the top five cancer practices or interventions that are "costly, widely used, and not supported by high-level clinical evidence", according to an article published in the Journal of Clinical Oncology. ASCO say that these interventions should not be administered unless careful consideration has been given to the appropriateness of use in individual cases. The top five are: • cancer-directed therapy for solid tumours in patients with low performance status (III or IV), not eligible for a clinical trial, with no benefit from prior evidence-based interventions or with no strong evidence supporting the clinical value of further treatment • PET ** , computed tomography (CT) or radionuclide bone scans (RBS) for staging of early prostate cancer in men at low risk of metastases • PET, CT or RBS for the staging of early breast cancer in women at low risk of metastases • surveillance biomarker testing or imaging (PET, CT or RBC) in asymptomatic breast cancer patients previously treated with curative intent • white cell stimulating factors for the primary prevention of febrile neutropenia in patients with a < 20% risk. The authors say that reconsidering the use of these five interventions "one patient at a time" is likely to "improve the value of care" provided at the "lowest cost to the patient and society". * American Society of Clinical Oncology ** positron emission tomography Schnipper LE, et al. American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology. Journal of Clinical Oncology : 3 Apr 2012. Available from: URL: http:// dx.doi.org/10.1200/jco.2012.42.8375 803069566 1 PharmacoEconomics & Outcomes News 28 Apr 2012 No. 652 1173-5503/10/0652-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

ASCO’s “top five“ costly overused interventions

Download PDF Report

Upload
lamnhan
View
215
Download
0

Embed Size (px)

Citation preview

PharmacoEconomics & Outcomes News 652 - 28 Apr 2012

ASCO’s "top five" costly overusedinterventions

ASCO* has identified the top five cancer practices orinterventions that are "costly, widely used, and notsupported by high-level clinical evidence", according toan article published in the Journal of Clinical Oncology.ASCO say that these interventions should not beadministered unless careful consideration has beengiven to the appropriateness of use in individual cases.The top five are:• cancer-directed therapy for solid tumours in patients

with low performance status (III or IV), not eligiblefor a clinical trial, with no benefit from priorevidence-based interventions or with no strongevidence supporting the clinical value of furthertreatment

• PET**, computed tomography (CT) or radionuclidebone scans (RBS) for staging of early prostate cancerin men at low risk of metastases

• PET, CT or RBS for the staging of early breast cancerin women at low risk of metastases

• surveillance biomarker testing or imaging (PET, CTor RBC) in asymptomatic breast cancer patientspreviously treated with curative intent

• white cell stimulating factors for the primaryprevention of febrile neutropenia in patients with a< 20% risk.

The authors say that reconsidering the use of thesefive interventions "one patient at a time" is likely to"improve the value of care" provided at the "lowest costto the patient and society".* American Society of Clinical Oncology** positron emission tomography

Schnipper LE, et al. American Society of Clinical Oncology Identifies Five KeyOpportunities to Improve Care and Reduce Costs: The Top Five List for Oncology.Journal of Clinical Oncology : 3 Apr 2012. Available from: URL: http://dx.doi.org/10.1200/jco.2012.42.8375 803069566